<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25887557</article-id><article-id pub-id-type="pmc">4336683</article-id><article-id pub-id-type="publisher-id">6</article-id><article-id pub-id-type="doi">10.1186/s12877-015-0006-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The protocol of the Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Neerland</surname><given-names>Bj&#x000f8;rn Erik</given-names></name><address><email>bjorn.erik@neerland.net</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hov</surname><given-names>Karen Roksund</given-names></name><address><email>karenroksundhov@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bruun Wyller</surname><given-names>Vegard</given-names></name><address><email>brwylle@online.no</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Qvigstad</surname><given-names>Eirik</given-names></name><address><email>eirik.qvigstad@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Skovlund</surname><given-names>Eva</given-names></name><address><email>eva.skovlund@farmasi.uio.no</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>MacLullich</surname><given-names>Alasdair MJ</given-names></name><address><email>a.maclullich@ed.ac.uk</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bruun Wyller</surname><given-names>Torgeir</given-names></name><address><email>t.b.wyller@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Oslo Delirium Research Group, Department of Geriatric Medicine, University of Oslo, Pb 4956, N-0424, Oslo, Norway </aff><aff id="Aff2"><label>2</label>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway </aff><aff id="Aff3"><label>3</label>Department of Pediatrics, Akershus University Hospital, L&#x000f8;renskog, Norway </aff><aff id="Aff4"><label>4</label>Institute of Clinical Medicine, University of Oslo, Oslo, Norway </aff><aff id="Aff5"><label>5</label>Department of Cardiology, Oslo University Hospital, Oslo, Norway </aff><aff id="Aff6"><label>6</label>School of Pharmacy, University of Oslo, Oslo, Norway </aff><aff id="Aff7"><label>7</label>Edinburgh Delirium Research Group, Geriatric Medicine, University of Edinburgh, Room F1424, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA UK </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>7</elocation-id><history><date date-type="received"><day>30</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Neerland et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Delirium affects 15% of hospitalised patients and is linked with poor outcomes, yet few pharmacological treatment options exist. One hypothesis is that delirium may in part result from exaggerated and/or prolonged stress responses. Dexmedetomidine, a parenterally-administered alpha2-adrenergic receptor agonist which attenuates sympathetic nervous system activity, shows promise as treatment in ICU delirium. Clonidine exhibits similar pharmacodynamic properties and can be administered orally. We therefore wish to explore possible effects of clonidine upon the duration and severity of delirium in general medical inpatients.</p></sec><sec><title>Methods/Design</title><p>The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is a randomised, placebo-controlled, double-blinded, parallel group study with 4-month prospective follow-up. We will recruit 100 older medical inpatients with delirium or subsyndromal delirium in the acute geriatric ward. Participants will be randomised to oral clonidine or placebo until delirium free for 2 days (Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria), or after a maximum of 7 days treatment. Assessment of haemodynamics (blood pressure, heart rate and electrocardiogram) and delirium will be performed daily until discharge or a maximum of 7 days after end of treatment. The primary endpoint is the trajectory of delirium over time (measured by Memorial Delirium Assessment Scale). Secondary endpoints include the duration of delirium, use of rescue medication for delirium, pharmacokinetics and pharmacodynamics of clonidine, cognitive function after 4 months, length of hospital stay and need for institutionalisation.</p></sec><sec><title>Discussion</title><p>LUCID will explore the efficacy and safety of clonidine for delirium in older medical inpatients.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01956604?term=LUCID&#x00026;rank=2">NCT01956604</ext-link>. EudraCT Number: 2013-000815-26</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Delirium</kwd><kwd>Treatment</kwd><kwd>Clonidine</kwd><kwd>Drug therapy</kwd><kwd>Double-blind method</kwd><kwd>Aged</kwd><kwd>Therapeutic use</kwd><kwd>Adrenergic alpha-2 Receptor Agonists</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><sec id="Sec2"><title>Delirium in hospitalised medical patients</title><p>Delirium commonly affects older people with acute medical illness [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. It is associated with patient distress, increased length of stay, higher risk of new institutionalisation, higher mortality, and an increased risk of future dementia [<xref ref-type="bibr" rid="CR3">3</xref>-<xref ref-type="bibr" rid="CR6">6</xref>]. Despite its impact, delirium remains poorly understood and few treatment options are available.</p><p>The prevalence of delirium is at least 15% in hospitalised medical patients [<xref ref-type="bibr" rid="CR7">7</xref>-<xref ref-type="bibr" rid="CR9">9</xref>]. In patients with dementia the prevalence is even higher, being up to 50 % in medical wards [<xref ref-type="bibr" rid="CR10">10</xref>]. Old age and pre-existing cognitive impairment are the most important predisposing factors for delirium [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR9">9</xref>], but, in principle, any acute medical condition can precipitate delirium in a vulnerable individual [<xref ref-type="bibr" rid="CR7">7</xref>]. Subsyndromal delirium is a clinical condition that falls on a continuum between no symptoms and delirium defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) [<xref ref-type="bibr" rid="CR11">11</xref>]. Subsyndromal delirium may progress to full-scale delirium, and is a clinically important condition associated with poor outcomes. Efforts to prevent, detect and treat subsyndromal delirium are thus justified.</p></sec><sec id="Sec3"><title>Pathophysiology of delirium</title><p>The pathophysiology of delirium remains poorly understood. Leading hypotheses focus on neurotransmission, inflammation and acute stress as possible mechanisms [<xref ref-type="bibr" rid="CR12">12</xref>]. Decreased cholinergic activity and increased dopaminergic activity in the central nervous system (CNS) are commonly postulated, with these neurotransmitter deficits resulting from multiple precipitants. A causal association between inflammation (pro-inflammatory cytokines) and delirium has also been proposed [<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]. Another hypothesis implies that delirium may be the result of aberrant stress responses [<xref ref-type="bibr" rid="CR13">13</xref>] as delirium commonly follows stress (physical or psychological). And whilst stress responses are adaptive in young people, they might be altered with ageing, leading to exaggerated and more prolonged stress responses. This hypothesis would also imply alterations of autonomic nervous system activity in patients with delirium [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Pharmacological treatment of delirium</title><p>The hyperactive form of delirium is frequently treated pharmacologically, but the effect of different treatment modalities is poorly studied. The drug treatment of hypoactive delirium has hardly been evaluated at all. Thus more research on pharmacological treatment options for delirium is urgently needed. Haloperidol [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>] and other antipsychotics (olanzapine [<xref ref-type="bibr" rid="CR18">18</xref>], risperidone [<xref ref-type="bibr" rid="CR19">19</xref>] and quetiapine [<xref ref-type="bibr" rid="CR20">20</xref>]) are commonly used, and there is some, although weak, evidence of their efficacy [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref>]. There is no evidence on the effects of antipsychotics in patients with delirium superimposed upon dementia. For patients with parkinsonism or dementia with Lewy bodies, antipsychotics are generally avoided, leaving even fewer treatment options for these patients.</p><p>Antipsychotics have several drawbacks, including an increased risk of death and cardiovascular events, sedation, falls risk, and cognitive impairment [<xref ref-type="bibr" rid="CR23">23</xref>]. These risks increase with age, dementia and disability. This calls for special caution for patients with delirium superimposed on dementia [<xref ref-type="bibr" rid="CR21">21</xref>]. Benzodiazepines and other sedatives are also frequently used, but the evidence supporting these agents is even weaker [<xref ref-type="bibr" rid="CR24">24</xref>]. There is no clear evidence for the efficacy of cholinesterase inhibitors in the treatment of delirium [<xref ref-type="bibr" rid="CR25">25</xref>-<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec5"><title>Alpha-2-adrenoreceptor agonists</title><p>Dexmedetomidine and clonidine are both alpha-2-adrenoceptor agonists activating presynaptic inhibitory alpha-2-adrenoreceptors. Clonidine is a partial agonist with an alpha-2a-to-alpha-1 selectivity ratio of 39. For dexmedetomidine this ratio is 1300 [<xref ref-type="bibr" rid="CR28">28</xref>]. They exert a general inhibitory influence on the sympathetic nervous system, in particular due to CNS effects [<xref ref-type="bibr" rid="CR29">29</xref>]. Dexmedetomidine decreases sympathetic activity and attenuates the hemodynamic and neuroendocrinal stress responses (including of cortisol), resulting in decreased heart rate (HR) and blood pressure (BP) as well as sedative and analgesic effects [<xref ref-type="bibr" rid="CR30">30</xref>]. In the intensive care setting, both substances reduce the need for opioids and sedatives [<xref ref-type="bibr" rid="CR31">31</xref>]. Dexmedetomidine is increasingly used in intensive care patients, and is also used as an adjuvant during regional anaesthesia. Recently conducted studies indicate that the incidence of delirium is lower in intensive care patients receiving dexmedetomidine than in those receiving benzodiazepines [<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>], propofol [<xref ref-type="bibr" rid="CR34">34</xref>] or morphine [<xref ref-type="bibr" rid="CR35">35</xref>]. Currently available evidence thus suggests that dexmedetomidine may have value in the prevention and treatment of delirium in the intensive care unit [<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref>]. Indeed, it is now in clinical use in the USA and Europe [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Most patients with delirium are however treated outside of intensive care units, where intravenous use of dexmedetomidine is not feasible. An alternative agent might thus be orally administred clonidine, which has very similar pharmacodynamics to that of dexmedetomidine [<xref ref-type="bibr" rid="CR31">31</xref>], even though its alpha-2 selectivity is somewhat lower [<xref ref-type="bibr" rid="CR28">28</xref>]. Clonidine additionally has an independent stimulatory effect on the parasympathetic activity and a slight anti-inflammatory effect [<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>], further making it an interesting candidate for delirium treatment. This does also accord with the hypothesis of delirium as a consequence of aberrant stress responses [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec6"><title>Clinical experience with clonidine</title><p>Clonidine has been used as an anti-hypertensive drug for decades, as well as for anesthesia-related applications, such as perioperative analgesia [<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR41">41</xref>], sedation and anxiolysis, and for management of both acute postoperative, chronic and neuropathic pain [<xref ref-type="bibr" rid="CR41">41</xref>-<xref ref-type="bibr" rid="CR43">43</xref>]. In one study, use of intravenous clonidine after surgical correction of acute type-A aortic dissection reduced the severity of delirium, improved the respiratory function and shortened the length of stay in the intensive care unit [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>The adverse effects of clonidine include orthostatic hypotension, bradycardia and AV-block. Such effects are, however, dependent on dosage. In a previous report, low-dose treatment (75&#x000a0;&#x003bc;g) in healthy adults was associated with a reduction in heart rate from 72 beats/min to 63 beats/min, and a reduction in mean arterial pressure (MAP) from 88&#x000a0;mmHg to 75&#x000a0;mmHg. Less than 50% experienced sedation, dry mouth or dizziness, and for those who reported any of these side-effects, the severity was mild [<xref ref-type="bibr" rid="CR45">45</xref>]. Clonidine has been studied in outpatients with Alzheimer's dementia [<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR47">47</xref>] and in patients with Parkinson's disease [<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref>]. Treatment with daily doses of clonidine less than 200 mcg was well tolerated in these patients. Relative contraindications to clonidine for its licensed indications include bradyarrhythmias, polyneuropathy, renal insufficiency and evidence of reduced cerebral and/or peripheral circulation due to vessel disease</p></sec><sec id="Sec7"><title>Pharmacokinetics of clonidine</title><p>Maximum plasma concentration (Cmax) following oral administration occurs after 1&#x02013;3&#x000a0;h [<xref ref-type="bibr" rid="CR45">45</xref>] and reduction in mean arterial pressure as well as the risk of side effects is highest at this peak. Cmax and area under the concentration-time-curve (AUC) increase proportionally with increasing doses. Clonidine traverses the blood&#x02013;brain-barrier. The half-life during the elimination phase shows great inter-individual variation and is found to be between 5 and 25.5&#x000a0;hours. The metabolism is hepatic and the metabolites are inactive. Clonidine is mainly excreted renally (70%).</p></sec><sec id="Sec8"><title>Rationale for dosage plan of clonidine</title><p>A dosage plan for clonidine is presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Because we are studying short-term use in an acute setting, we want to achieve steady-state (serum concentration levels) more quickly by using loading doses (day 1) under close monitoring of blood pressure. On days 2&#x02013;7 we will administer a lower maintenance dose. We will thus give 75&#x000a0;&#x003bc;g clonidine every 3<sup>rd</sup> hour up to a maximum of 4 doses on day 1, and then 75&#x000a0;&#x003bc;g twice per day.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Dosage plan for clonidine</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Safety</th><th>Dosage</th></tr></thead><tbody><tr><td>Day 1</td><td>Systolic BP has to be &#x0003e;120&#x000a0;mmHg before the first loading dose.</td><td rowspan="3">75&#x000a0;&#x003bc;g every 3<sup>rd</sup> hour until maximum 4 doses, (e.g.: at 2, 5, 8 and 11 p.m)</td></tr><tr><td rowspan="2">Loading doses</td><td>If systolic BP is &#x0003c;100&#x000a0;mmHg, HR &#x0003c;50 beats/min, or if RASS is &#x02212;3 or less before any of the subsequent loading doses, no more study medication will be given until the planned maintenance dose the next morning.</td></tr><tr><td>If RASS is &#x02212;2, the treating physician has to assess if IMP will be given or not</td></tr><tr><td>Day 2-7</td><td rowspan="2">If systolic BP is &#x0003c;100&#x000a0;mmHg, HR &#x0003c;50 beats/min, or if RASS is &#x02212;3 or less just before a planned dose, no study medication will be given until the next planned dose 12&#x000a0;hours later.</td><td rowspan="3">75&#x000a0;&#x003bc;g BID, at 8&#x02013;9 a.m and 8&#x02013;9 p.m</td></tr><tr><td rowspan="2">Maintenance doses</td></tr><tr><td>If RASS is &#x02212;2, the treating physician has to assess if IMP will be given or not</td></tr></tbody></table></table-wrap></p><p>Concentration levels of clonidine known to have clinical effects range from 0.2 to 2.0 ng/ml [<xref ref-type="bibr" rid="CR50">50</xref>-<xref ref-type="bibr" rid="CR52">52</xref>]. We are aiming for the lower levels, that is, between 0.3 ng/ml (median trough concentration) and 0.7 ng/ml (maximal concentration), because higher plasma concentration levels increases the risk of adverse events, including hypotension. Nonetheless, lower plasma concentration levels may be insufficient to give a significant effect on our primary endpoint.</p><p>To our knowledge, there are no studies of the relationship between plasma concentration of clonidine and delirium. In publications on the effect on delirium of dexmedetomidine, the plasma concentration levels are not reported. Additionally, dexmedetomidine is approximately 8 times more selective (alpha 2 versus alpha 1) than clonidine [<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR31">31</xref>], and so pharmacokinetic data on dexmedetomidine cannot be used to estimate effective doses of clonidine. We thus have to extrapolate from pharmacokinetic data on clonidine used for other purposes. We know that clonidine has both sedative and anxiolytic effects, and that these centrally mediated effects are closely related to plasma concentration levels [<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>In a study of adolescents with chronic fatigue syndrome, a dosage of 50 &#x003bc;g twice per day resulted in a median trough concentration (C<sub>0</sub>) at 0.21 &#x003bc;g/L after 14 days of treatment, rising to a median level of 0.41 &#x003bc;g/L (C<sub>max</sub>) two hours after administration of one regular dose of 50 &#x003bc;g [<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref>]. In a study of healthy normotensive subjects, treatment with oral clonidine 225 &#x003bc;g daily for one week resulted in a steady state of 0.3-0.35 ng/ml. After intake of one 75 &#x003bc;g tablet, the serum level then increased to 0.7 ng/ml at 2 h. There was a significant relationship between the plasma level of clonidine and sedation [<xref ref-type="bibr" rid="CR53">53</xref>]. In subjects receiving oral clonidine 100 &#x003bc;g twice per day for 6 weeks, plasma concentration ranged between 0.4 and 0.7 ng/ml (levels 2 hours after intake of 100 &#x003bc;g) [<xref ref-type="bibr" rid="CR52">52</xref>]. Another study found that a single dose of 75 &#x003bc;g gave a Cmax of 0.66 ng/ml after achieving steady-state with two 75 &#x003bc;g doses [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p>The present patient population (elderly with a glomerular filtration rate [GFR] limit of&#x02009;&#x0003e;&#x02009;30&#x000a0;ml/min) may have a longer half life of clonidine due to a diminished renal capacity as compared to younger. Altough the metabolism of clonidine is hepatic, varying amounts of unmetabolised clonidine is secreted renally. Consequently, patients may also have a higher risk of adverse events related to the study drug. We therefore choose a lower dosage, considered safe, of 75&#x000a0;&#x003bc;g twice per day.</p></sec><sec id="Sec9"><title>Loading doses</title><p>The loading dose is based on half-life. Clonidine follows first order kinetics for elimination, and thus the mean steady state is proportional to the daily dose. Doubling the total daily dose should double the mean plasma concentration level. A study showed that a single oral dose of 75ug clonidine gave Cmax 0.29&#x000a0;ng/ml, 150ug gave Cmax 0.61&#x000a0;ng/ml and 250ug gave 1.2&#x000a0;ng/ml [<xref ref-type="bibr" rid="CR45">45</xref>]. We will administer up to 300&#x000a0;&#x003bc;g the first day, but as 75 ug every three hours. Thus, the theoretical Cmax at day one would be significantly lower than 1.2&#x000a0;ng/ml, due to elimination of the drug. How much lower is difficult to estimate, given the large variability in half-life (5 to 25&#x000a0;hours).</p><p>The expected maximum hypotensive effect correlates well with the Cmax time-point occurring after 2&#x000a0;hours. There is an interindividual difference in the pharmacodynamic response to clonidine. Our loading dose is dependent on and monitored by the individual patients' haemodynamic response (blood pressure and heart rate).</p></sec><sec id="Sec10"><title>Safety review</title><p>A safety review will be done after we have recruited 20 patients (10 placebo and 10 clonidine). Recruitment of the additional 80 patients will be halted until we have made an assessment of the serum concentration levels, pharmacokinetics and -dynamics (the haemodynamic response) in these initial 20 patients. These data will then guide further dosage for the subsequent 80 patients. We are aiming for serum concentration levels between 0.3 and 0.7&#x000a0;ng/ml, but may accept a small number of single measures above this range. Blood samples for serum concentration measurement will be taken 3&#x000a0;hours after the patient has taken the study drug (each time) on day 1 and just before administration of study drug between 0800 and 0900 on day 2. The serum concentration levels and pharmacodynamic responses will be assessed by an independent Data Monitoring Committee. The determination of the further dosage plan will thus be based on both pharmacokinetics/serum concentration levels and the individual patients&#x000b4; haemodynamic responses. The further dosage plan will be approved by The Norwegian Medicines Agency.</p></sec></sec><sec id="Sec11"><title>Study objectives</title><sec id="Sec12"><title>Primary endpoint</title><p>The endpoints and measurements for efficacy assessment are listed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Our primary objective is to explore the potential superiority of clonidine vs placebo in decreasing delirium duration and severity, measured by Memorial Delirium Assessment Scale (MDAS) [<xref ref-type="bibr" rid="CR58">58</xref>] in patients diagnosed with delirium or subsyndromal delirium (according to Diagnostic and Statistical Manual of Mental Disorders, DSM-5 [<xref ref-type="bibr" rid="CR59">59</xref>]). The primary endpoint, the trajectory of delirium, is the severity of delirium (measured by MDAS) over time.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>List of endpoints and measurements for efficacy assessment</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Endpoint</th><th>Measurements for efficacy assessment</th></tr></thead><tbody><tr><td colspan="2">
<bold>Primary</bold>
</td></tr><tr><td>Delirium trajectory</td><td>MDAS</td></tr><tr><td colspan="2"><bold>Secondary</bold> (also with subanalyses for subsyndromal delirium and hypoactive/hyperactive/mixed delirium)</td></tr><tr><td>Time-to-first delirium resolution</td><td>DSM-5</td></tr><tr><td>Incidence of &#x0201c;full-scale&#x0201d; delirium</td><td>DSM-5</td></tr><tr><td>Severity of delirium</td><td>MDAS, OSLA</td></tr><tr><td>Delirium subtype</td><td>MDAS, OSLA, DelApp</td></tr><tr><td>Use of &#x0201c;rescue medication&#x0201d;/additional drugs (as other sedatives, analgetics and antipsychotics)</td><td>Registration of use of all medication</td></tr><tr><td>Length of hospital stay</td><td>Registrations</td></tr><tr><td>Patient distress</td><td>Checklist of Nonverbal Pain Indicators</td></tr><tr><td>Cognitive function in follow-up after 4&#x000a0;months</td><td>MMSE-NR, Clock drawing test, Ten-words memory test, Trial making test A and B, IQCODE, CDR</td></tr><tr><td>Independence in follow-up after 4&#x000a0;months</td><td>Barthel ADL, NEADL</td></tr><tr><td>Pharmacokinetic response to clonidine</td><td>Serum drug concentrations</td></tr><tr><td>Pharmacodynamic response to clonidine</td><td>BP, HR, ECG, RASS, OSLA, symptoms of bradycardia, orthostatic hypotension or other side-effects</td></tr><tr><td>Biomarkers</td><td>Blood samples</td></tr><tr><td>Institutionalisation</td><td>Registrations</td></tr><tr><td>Survival</td><td>Registrations</td></tr><tr><td colspan="2">
<bold>Safety</bold>
</td></tr><tr><td>Side effects of clonidine/in-hospital complications</td><td>BP, HR, ECG, sedation (RASS, OSLA), and any symptoms of bradycardia, orthostatic hypotension or other side-effects</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Secondary endpoints</title><p>We will compare the actively treated group with the placebo group with respect to secondary endpoints shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The main secondary endpoint is the duration of delirium monitored daily by the DSM-5 diagnostic criteria. We will also study the feasibility of oral clonidine in a geriatric ward and effects of clonidine upon a variety of outcomes as a means to design a potentially more definite study later. We will do per protocol analyses and exposure-response analyses based on plasma-concentration.</p></sec></sec><sec id="Sec14"><title>Methods and design</title><sec id="Sec15"><title>Study design</title><p>The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is a randomised, placebo-controlled, double-blinded, parallel group study with 4&#x000a0;month prospective follow-up (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). We aim to include 100 inpatients with delirium (or subsyndromal delirium) in an acute geriatric ward. Patients will be randomised to orally administrated clonidine or placebo until delirium free (by DSM-5 criteria) or no subsyndromal delirium for 2&#x000a0;days, or after a maximum of 7&#x000a0;days treatment. If the treating physician plan to discharge the patient (still having delirium/subsyndromal delirium), before 7&#x000a0;days, we will end the treatment 24&#x000a0;hours before discharge. Assessment of haemodynamics (blood pressure, heart rate and ECG) and of delirium will be performed daily until discharge, or a maximum of 7&#x000a0;days after end of treatment.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>CONSORT Study flow diagram.</bold>
</p></caption><graphic xlink:href="12877_2015_6_Fig1_HTML" id="d30e1063"/></fig></p><p>This study will be conducted in compliance with the Declaration of Helsinki and with ICH/Good Clinical Practice. Registration of patient data will be carried out in accordance with national personal data laws. The study design, protocol and informed consent procedures are approved by the Regional Medical Ethics Committee and the Norwegian Medicines Agency (EUDRACT number 2013-000815-26). The study is also registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT01956604).</p></sec><sec id="Sec16"><title>Study population</title><p>We will recruit patients &#x0003e;65&#x000a0;years of age from the acute geriatric ward at Oslo University Hospital. These patients are usually acutely admitted, arriving directly from the emergency department, with considerable multimorbidity and polypharmacy, with a high prevalence of infections, dehydration, acute cardiac problems, general medical problems, functional decline and delirium. They might be included at admission (prevalent delirium), or during the stay (incident delirium). Patients with prevalent delirium/subsyndromal delirium must be included within approximately 48&#x000a0;hours after admission and patients with incident delirium/subsyndromal delirium must be included within approximately 48&#x000a0;hours of symptom onset. All patients must have current delirium/subsyndromal delirium at the time of inclusion.</p></sec><sec id="Sec17"><title>Screening</title><p>Patients admitted to the study ward will go through a simple screening process (see Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). This screening is a combination of the Single Question in Delirium (SQiD) (asking one question to the patient's friend or relative:&#x0201d; Do you think (name) has been more confused in the last two weeks?&#x0201d;) [<xref ref-type="bibr" rid="CR60">60</xref>], combined with two simple attention tests (reciting the days of the week and months of the year backwards). If any of these tests are positive, if the patient is drowsy, or if the nurse and/or the treating physician for other reasons suspects delirium, ascertainment of delirium or subsyndromal delirium will be performed.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Screening for delirium in patients at the acute geriatric ward</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>Yes</th><th>No</th></tr></thead><tbody><tr><td rowspan="5">Screening</td><td>SQiD</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Drowsiness</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Cannot recite months backwards (unable to reach July)</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Cannot recite all the weekdays backwards</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Staff suspect delirium</td><td>&#x025a1;</td><td>&#x025a1;</td></tr><tr><td>Ascertainment of delirium or subsyndromal delirium</td><td colspan="3">If Yes in any box, do diagnostic procedure (DSM-5), Table 4</td></tr><tr><td rowspan="2">Inclusion</td><td colspan="3">All DSM-5 criteria (delirium) or subsyndromal delirium&#x02009;&#x02192;&#x02009;can be included</td></tr><tr><td colspan="3">If the patient meets all the inclusion criteria, the patient will be included</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec18"><title>Diagnosis of delirium and subsyndromal delirium</title><p>The diagnosis of delirium will be made by the study physicians according to DSM-5 criteria by using a standardised procedure (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Level of arousal will be assessed using the Richmond Agitation and Sedation Scale (RASS) [<xref ref-type="bibr" rid="CR61">61</xref>] and the Observational Scale of Level of Arousal (OSLA) [<xref ref-type="bibr" rid="CR62">62</xref>]. Attention will be evaluated using objective tests (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) and observations by the examiner of the patient&#x000b4;s distractibility, comprehension and tendency to lose the thread of conversation. We will also use a smartphone (Android) software application, the &#x0201c;DelApp&#x0201d; [<xref ref-type="bibr" rid="CR63">63</xref>], which incorporates an initial test of level of arousal followed by a test of attention. Acute change in the patient&#x000b4;s mental status, and fluctuation of any disturbance, will be ascertained through informant history from nursing staff and carers and also derived from clinical notes. Assessment of additional mental status disturbances will be performed by asking the patient a list of pre-defined questions (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) in addition to information derived from nursing staff and clinical notes. All these assessments will be used in combination in relation to the DSM-5 criteria. The objective indicators (described above and in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) will be supplemented by the assessor&#x000b4;s judgement regarding subjective features and a final diagnosis made.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Diagnostic algorithm for DSM-5 delirium</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">DSM-5 criteria</th><th rowspan="2" colspan="3">Tests to be performed or information needed</th><th colspan="2">DSM-5 criteria fullfilled?</th></tr><tr><th>YES</th><th>NO</th></tr></thead><tbody><tr><td rowspan="10">A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment).</td><td>
<bold>Evaluation</bold>
</td><td>
<bold>TEST</bold>
</td><td>
<bold>Cut off (definition of inattention)</bold>
</td><td rowspan="10"/><td rowspan="10"/></tr><tr><td>
<bold>Daily</bold>
</td><td>Digit span forward</td><td>Less than 5 forward</td></tr><tr><td>
<bold>Daily</bold>
</td><td>Digit span backward</td><td>Less than 3 backwards</td></tr><tr><td>
<bold>Daily</bold>
</td><td>SAVEAHAART</td><td>2 or more errors</td></tr><tr><td>
<bold>Initial diagnosis only</bold>
</td><td>Days of the week in reverse order</td><td>Any error</td></tr><tr><td>
<bold>Initial diagnosis only</bold>
</td><td>Months of the year in reverse order</td><td>Unable to reach July</td></tr><tr><td>
<bold>Initial diagnosis only</bold>
</td><td>Count backwards from 20 to 1</td><td>Any error</td></tr><tr><td colspan="3">Observation (by the examiner):</td></tr><tr><td colspan="3">Distractibility. Comprehension. Tendency to lose the tread of conversation</td></tr><tr><td colspan="3">The &#x0201c;DelApp&#x0201d; [level of arousal test followed by counting of serially-presented lights. Cut-off 7/8 out of 10]</td></tr><tr><td rowspan="6">B. The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day.</td><td colspan="3">Informant history from patient&#x000b4;s carers and nursing staff</td><td rowspan="2"/><td rowspan="2"/></tr><tr><td colspan="3">Questions to carer/ nursing staff or derived from clinical notes:</td></tr><tr><td colspan="3">Has there been a sudden change in the patient&#x000b4;s mental state?</td><td rowspan="4"/><td rowspan="4"/></tr><tr><td colspan="3">Does the patient seem to be better at any period in the day compared to other times?</td></tr><tr><td colspan="3">Has the level of consciousness been altered (drowsy/not interacting or agitated)?</td></tr><tr><td colspan="3">Sleep-wake cycle disturbances?</td></tr><tr><td rowspan="8">C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).</td><td colspan="3">Questions to the patient:</td><td rowspan="8"/><td rowspan="8"/></tr><tr><td colspan="3">Orientation to time, place and person</td></tr><tr><td colspan="3">Recall (3 words)</td></tr><tr><td colspan="3">Why are you in hospital? Will a stone float in water? Are there fish in the sea? (any error&#x02009;=&#x02009;disorganised thinking)</td></tr><tr><td colspan="3">Questions to carer/ nursing staff or derived from clinical notes:</td></tr><tr><td colspan="3">Has there been any&#x02026;:</td></tr><tr><td colspan="3">Perceptual disturbances? Sleep-wake cycle disturbances? Memory disturbances? Psychotic symptoms?</td></tr><tr><td colspan="3">Psychomotor abnormalities?</td></tr><tr><td>D. The disturbances in criteria A and C are not explained by another preexisting, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal, such as coma.</td><td colspan="3">Information from history/chart/clinical assessment</td><td/><td/></tr><tr><td>E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiologic consequence of another medical condition, substance intoxication or withdrawal (i.e., because of a drug of abuse or to a medication), or exposure to a toxin or is because of multiple etiologies.</td><td colspan="3">Information from history/chart/clinical assessment</td><td/><td/></tr><tr><td>Delirium based on the tests and information above?</td><td colspan="3">All DSM-5 criteria fulfilled</td><td>Yes &#x025a1;</td><td>No &#x025a1;</td></tr><tr><td rowspan="2">Subsyndromal delirium based on the tests and information above?</td><td colspan="3">Defined as evidence of change, in addition to any one of these: (a) altered arousal, (b) attentional deficits, (c) other cognitive change, (d) delusions or hallucinations.</td><td rowspan="2">Yes &#x025a1;</td><td rowspan="2">No &#x025a1;</td></tr><tr><td colspan="3">Criteria D and E must be met.</td></tr></tbody></table></table-wrap></p><p>Subsyndromal delirium will be defined as evidence of change, in addition to any one of these: (a) altered arousal, (b) attentional deficits, (c) other cognitive change, (d) delusions or hallucinations. DSM-5 criteria D and E must be met. The severity of delirium will be assessed for all included patients by MDAS [<xref ref-type="bibr" rid="CR58">58</xref>], based on the tests and information described above. We will also register the Confusion Assessment Method (CAM) [<xref ref-type="bibr" rid="CR64">64</xref>] daily.</p></sec><sec id="Sec19"><title>Evaluating patient eligibility</title><p>According to the inclusion and exclusion criteria, ECG, creatinine/eGFR, body weight and blood pressure measurements are required. The final decision on eligibility will be agreed with the treating physician on the ward. Capacity will be assessed and informed consent (and/or) assent obtained (see below).</p></sec><sec id="Sec20"><title>Inclusion and exclusion criteria</title><p>Patients with delirium or subsyndromal delirium will be included in this study by the study physicians. We will include patients with chronic cognitive impairment or dementia as well as patients free from dementia. Nursing home patients are eligible. Patients must be &#x0003e; 65 years old, though the average age is expected to be more than 80 years. Further, the patient must be willing and able to receive the study medication.</p><p>
<bold>Inclusion criteria</bold>
</p><p>All of the following conditions must apply to the prospective patient at screening prior to receiving study agent:<list list-type="bullet"><list-item><p>Patient &#x0003e; 65 years old admitted to the acute, medical, geriatric ward</p></list-item><list-item><p>Delirium or subsyndromal delirium within the last 48 hours</p></list-item><list-item><p>Signed informed consent from patient or relatives and expected cooperation of the patients for the treatment and follow up must be obtained and documented</p></list-item></list></p><p>
<bold>Exclusion criteria</bold>
</p><p>Patients will be excluded from the study if they meet any of the following criteria:<list list-type="bullet"><list-item><p>Symptomatic bradycardia, bradycardia due to sick-sinus-syndrome, second- or third- degree AV-block (if not treated with pacemaker) or any other reason causing HR &#x0003c;50 bpm at time of inclusion [<xref ref-type="bibr" rid="CR44">44</xref>].</p></list-item><list-item><p>Symptomatic hypotension or orthostatic hypotension, or a systolic BP &#x0003c;120 at the time of inclusion</p></list-item><list-item><p>Ischemic stroke within the last 3 months or critical peripheral ischemia</p></list-item><list-item><p>Acute coronary syndrome, unstable or severe coronary heart disease (symptoms at minimal physical activity; NYHA 3 and 4) and moderate to severe heart failure (NYHA 3 and 4). (Acute coronary syndrome is defined according to international guidelines)</p></list-item><list-item><p>A diagnosis of polyneuropathy, phaeochromocytoma or renal insufficiency (estimated GFR &#x0003c; 30 ml/min according to the MDRD formula) [<xref ref-type="bibr" rid="CR44">44</xref>]</p></list-item><list-item><p>Body weight &#x0003c;45 kg</p></list-item><list-item><p>Considered as moribund on admission</p></list-item><list-item><p>Unable to take oral medications</p></list-item><list-item><p>Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin</p></list-item><list-item><p>Previously included in this study</p></list-item><list-item><p>Adverse reactions to clonidine or excipients (lactose, saccharose)</p></list-item><list-item><p>Not speaking or reading Norwegian</p></list-item><list-item><p>Any other condition as evaluated by the treating physician</p></list-item></list></p></sec><sec id="Sec21"><title>Informed consent and enrolment</title><p>Informed consent is a well-known challenge in studies of delirium [<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref>], both due to the nature of delirium itself and the fact that people with underlying dementia are most at risk of developing delirium. Cognitively intact patients are included in this study on the basis of written, informed consent. We have developed a comprehensive information leaflet for cognitively intact patients and a simplified and shortened version for those who are partly or not at all competent to give their consent. For patients considered to lack capacity (due to severe delirium and/or dementia), but who are willing to take part, we will obtain proxy informed consent from a close relative. Consent to remain in the research will be obtained as soon as possible if capacity returns. Due to the importance of including patients as soon as possible after the diagnosis of delirium is made, the close relatives may give verbal consent (by phone) before randomisation and the written consent will be obtained as soon as possible after inclusion. We have good experience with this method from previous studies in our research group [<xref ref-type="bibr" rid="CR67">67</xref>].</p></sec><sec id="Sec22"><title>Randomisation and blinding</title><p>The randomisation is based on computer-generated random numbers, and will be carried out by a statistician. The randomisation schedule will be distributed to the producer of the study medication, and capsules made accordingly. The randomisation will be stratified with respect to whether or not the patient was admitted from a nursing home, in order to balance the groups with respect to pre-admission cognitive decline, independence and comorbidity, all important prognostic factors.</p></sec><sec id="Sec23"><title>Study medication</title><p>Each capsule (CAPSUGEL) will contain either 75&#x000a0;&#x003bc;g Catapresan (clonidine hydrochloride) or 75&#x000a0;&#x003bc;g placebo, and will be produced and labeled by Krager&#x000f8; tablettproduksjon A/S. The capsules containing active medication and placebo will look identical. If other medications are indicated for the treatment of delirium, the treating physician will prescribe this as &#x0201c;standard care&#x0201d;.</p></sec><sec id="Sec24"><title>Monitoring and safety</title><p>BP and HR will be monitored 3&#x000a0;hours after each loading dose (day 1) and then just before every dose. If there are signs of significant hypotension (systolic BP &#x0003c;100&#x000a0;mmHg) or bradycardia (heart rate &#x0003c;50 beats/min), further monitoring or treatment will be considered individually. During the whole treatment period blood pressure and heart rate will be assessed twice per day. ECG, serum creatinine, blood glucose and a clinical assessment by a physician (hydration, side-effects, RASS [<xref ref-type="bibr" rid="CR61">61</xref>] and OSLA [<xref ref-type="bibr" rid="CR62">62</xref>]) will be performed daily. Orthostatic BPtests will be performed during the hospital stay at day 5, 6 or 7 at 1100 (approximately 3&#x000a0;hours after administration of study drug).</p><p>For all patients, drug concentration (mean concentration just before intake and Cmax 3&#x000a0;hours after intake) will be measured at day 5, 6 or 7. The pharmacokinetics of clonidine varies inter-individually, possibly influencing individual treatment responses. But due to the short treatment period, measurement of drug concentration for individual drug modification is not feasible.</p></sec><sec id="Sec25"><title>Data collection</title><p>Demographic data, medical history, information regarding the acute underlying medical disease(s), drug use and proxy information will be collected during the hospital stay. Once included in the study, patients will be visited daily for efficacy and safety evaluations by the study physicians (geriatricians) or by the consultant on-call during the weekend.</p><p>We will assess pre-existent functional and cognitive status by asking the patient&#x02019;s primary caregiver (the best available source) to complete questionnaires to assess the patient&#x000b4;s functional and cognitive state two weeks prior to hospital admission. Functional status will be assessed using the Barthel ADL Index [<xref ref-type="bibr" rid="CR69">69</xref>] and the Nottingham Extended ADL Index (NEADL) [<xref ref-type="bibr" rid="CR70">70</xref>]. To ascertain prior long-term cognitive decline we will use the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [<xref ref-type="bibr" rid="CR71">71</xref>] and the Clinical Dementia Rating Scale (CDR) [<xref ref-type="bibr" rid="CR72">72</xref>]. The Mini-Mental State Evaluation &#x02013; Norwegian version (MMSE-NR) [<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref>] will be performed at baseline and at discharge for the purposes of general cognitive screening. The Cornell Depression Scale [<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref>] is based on proxy information and will be used to evaluate the degree of depressive symptoms.</p><p>Grip strength of the dominant hand will be measured using hand-held dynamometry once during the hospital stay and at follow-up after 4&#x000a0;months. The severity and number of comorbidities will be scored using the Cumulative Illness Rating Scale (CIRS) [<xref ref-type="bibr" rid="CR77">77</xref>]. The level of physiological disturbance will be assessed by using Acute Physiology and Chronic Health Evaluation II (APACHE II) [<xref ref-type="bibr" rid="CR78">78</xref>], the version utilising venous bicarbonate rather than arterial blood gases. Body Mass Index is registered as a marker of nutritional status.</p><p>We will use the algorithm described in the section above and in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> to diagnose delirium (or subsyndromal delirium) according to the DSM-5 criteria.</p><p>We will also collect data about patient distress, using items from The Checklist of Nonverbal Pain Indicators (CNPI) [<xref ref-type="bibr" rid="CR79">79</xref>]. Possible and suggestive causes of delirium are registered in each case at discharge.</p></sec><sec id="Sec26"><title>Laboratory tests and blood sample procedures</title><p>Data from routine blood samples taken at admission will be recorded (including Erythrocyte Sedimentation Rate, Haemoglobin, Leukocytes, Creatinine, Electrolytes, C-reactive protein, Albumin, Thyroid stimulating hormone and free Thyroxine levels).</p><p>All patients will have blood drawn for drug concentration levels at day 5, 6 or 7 (just before and 3&#x000a0;hours after intake of study medication), to be able to compare possible effects and side-effects to the actual plasma-concentration at the end of the trial.</p><p>Our study population is expected to have significant acute and chronic comorbidity. In this aspect, looking for new biomarkers is challenging, as we do not have a delirium-free control group. We will however take blood samples (serum and plasma) for biomarkers at inclusion, at mid-stay (day 3&#x02013;5) and at discharge, to explore markers already known to be associated with delirium. Interesting biomarker candidates include S100B [<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref>], neopterin [<xref ref-type="bibr" rid="CR82">82</xref>], IGF-1 [<xref ref-type="bibr" rid="CR83">83</xref>], MMP-9, protein C, sTNFR1 [<xref ref-type="bibr" rid="CR84">84</xref>]. The serum and plasma will be stored in a biobank freezer at Oslo University Hospital together with blood stored in EDTA tubes for possible DNA-analyses.</p></sec><sec id="Sec27"><title>Follow-up assessments</title><p>We will phone the patient or care-taker by phone one week after the end of the treatment to consider possible side-effects/ rebound effects or relapse of the delirium. No physical examination or psychometric tests will be performed. We will register the level of care, and whether the patient has been discharged home or to an institution.</p><p>Four months after discharge, a home visit will be done to perform cognitive tests (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Based on proxy information, we will evaluate each patient&#x000b4;s level of independence and functional and cognitive status. We will assess the presence of persistent delirium (according to DSM-5 criteria) and subsyndromal delirium and perform the MDAS. Grip strength will be measured. Level of care, any readmissions to hospital and cumulative mortality will be registered.. Causes of death will be ascertained from the Cause of Death Register.</p></sec><sec id="Sec28"><title>Criteria for patient discontinuation</title><p>Patients may be discontinued from study treatment and assessments for several reasons. These include: omission of more than 3 following dosages, voluntary discontinuation by the patient, safety reasons as judged by the study physician or treating physician, or significant non-compliance with the protocol as judged by the study physician. Any patient withdrawn from the study will be included in the statistical intention-to-treat analysis. If possible, a final assessment shall be made (end of study visit) and the reason for discontinuation shall be recorded. Progression of delirium is not a discontinuation criterion, as the trajectories are variable and impossible to predict. Progression of delirium may however make the patient unwilling to further participate. If any of the exclusion criteria appear during the treatment, treatment will be discontinued. (Except changes in blood pressure and heart rate, which will be managed as described in the dosage plan).</p></sec><sec id="Sec29"><title>Statistical analysis</title><p>The primary endpoint is the repeated measurements of MDAS over time. Differences in the MDAS trajectories between the treatment groups will be analysed by a mixed linear model. In addition we will, as a secondary endpoint, compare the time to resolution of delirium as measured by DSM-5. The Kaplan Meier method and the logrank test will be applied. In addition a Cox proportional hazards model will be applied to estimate hazard ratios. The additional different secondary endpoints will be analysed by t-tests when variables are continuous and by chi-square tests when variables are categorical. Patient survival will be compared between groups by the logrank test and Cox proportional hazards model.</p><p>For the comparison of the MDAS trajectories no adjustment for multiplicity will be applied. If a statistically significant difference between the MDAS trajectories is demonstrated, analyses of secondary endpoints will be performed without any formal adjustment for multiplicity. If any conclusion on efficacy is to be drawn based on a secondary endpoint only, a simple Bonferroni adjustment (dividing the 5% level with the actual number of tests performed) will be applied. If the use of additional antipsychotics differs between treatment groups, the amount calculated as haloperidol equivalents [<xref ref-type="bibr" rid="CR68">68</xref>] will be included in the statistical model.</p></sec><sec id="Sec30"><title>Sample size, statistical power and statistical analysis</title><p>Based on the expected number of patients fulfilling the inclusion criteria within 36&#x000a0;months a sample size of n&#x02009;=&#x02009;100 was chosen. Inclusion of 100 patients would lead to a power of only 71% to detect an absolute treatment difference of 25% in proportion recovered according to DSM-% (40% vs 65%). Correspondingly, using MDAS at one single point in time as the response measure would lead to approximately 80% power assuming a standard deviation of 9 and a difference in mean MDAS score of 5. Thus, analyzing treatment efficacy at only one point in time would lead to low power. An analysis of repeated measurements will reduce random variability and thereby increase power. The primary analysis is therefore a mixed linear model taking all MDAS measurements into account.</p><p>The expected efficiency gain is difficult to estimate precisely, but assuming a standard deviation of 9 on the MDAS and a correlation between measurements of r&#x02009;=&#x02009;0.5, the power would be around 95% to detect a mean MDAS difference of 5 or a power of 80% to detect a mean difference of 3.5 between groups.</p></sec></sec><sec id="Sec31" sec-type="discussion"><title>Discussion</title><p>Delirium is a severe and common condition among acute hospitalised elderly patients, and the options for pharmacological treatment are sparse. To our knowledge, no randomised placebo controlled trial investigating treatment of delirium with clonidine or other alpha-2-adrenoreceptor agonists has yet been done in non-critically ill medical patients. It has been recommended [<xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref>] that future studies on pharmacological treatment of delirium should have less restrictive exclusion criteria, in order to avoid low external validity. Further, future studies should ensure stratification according to known underlying risk factors for delirium. The trials should then have a true placebo arm and use validated instruments for delirium assessments. We have planned this trial according to these guidelines.</p><p>The results of our study will be more clinically relevant if the medication is easy and safe to administer to patients in a general ward, without the need for invasive monitoring. Frail and demented patients are more prone to develop delirium, and the treatment regimen should be feasible for this large group of patients. Thus, it is important that the exclusion criteria are not too strict, and we will therefore include patients with dementia and patients from nursing homes in this trial.</p><p>Delirium is a clinical diagnosis, based on history, information from proxies, mental status examination and evaluation of an underlying medical cause. There is no single simple test, neither psychometric nor physiological, to ascertain delirium. We have described the procedure that we will use to make the final diagnosis according to the DSM-5 criteria. All assessments of delirium will be made by the investigators (geriatricians trained in delirium evaluation) during weekdays, and by geriatricians on call in the weekends.</p><p>The primary outcome in this study is the trajectory of delirium, measured daily by MDAS. Due to features common in studies of delirium (small sample sizes, sample attrition, fluctuation course of the disease and spontaneous recovery), techniques that use all available data and take a global (as opposed to end-of-trial) perspective are preferred [<xref ref-type="bibr" rid="CR87">87</xref>]. Using longitudinal trajectories as the main outcome will almost always have greater power than end-of-trial analyses [<xref ref-type="bibr" rid="CR87">87</xref>-<xref ref-type="bibr" rid="CR89">89</xref>], as well as reducing the problem with missing data.</p><p>It is important to determine whether clonidine will have a differential impact on hyperactive versus hypoactive subtypes of delirium, or even only on certain features of delirium (e.g. inattention). The sample size of this study is too small to give conclusive results regarding secondary endpoints. However, these secondary objectives are exploratory and may generate new hypotheses and give direction for future studies.</p><p>Any positive results of clonidine on delirium symptoms will also contribute to the discussion about the underlying pathophysiology and the role of the autonomic nervous system in delirium. Studies of dexmedetomidine have showed promising results with respect to delirium duration and severity in the intensive care unit patients, but it is still uncertain weather this is an opioid- and benzodiazepine-sparing effect alone or if dexmedetomidine has truly delirium modulating effects [<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref>]. Any positive effect of clonidine compared to placebo may indicate that the sympathetic nervous system and related stress systems are involved in the underlying pathophysiology of delirium.</p></sec><sec id="Sec32" sec-type="conclusion"><title>Conclusion</title><p>LUCID will contribute to knowledge about the pharmacological treatment of delirium in the elderly, and may also shed light on relevant pathophysiological hypotheses.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADL</term><def><p>Activities of daily living</p></def></def-item><def-item><term>AV- block</term><def><p>Atrioventricular block</p></def></def-item><def-item><term>BID</term><def><p>Twice daily (bis in die)</p></def></def-item><def-item><term>BP</term><def><p>Blood Pressure</p></def></def-item><def-item><term>BPM</term><def><p>Beats per minute</p></def></def-item><def-item><term>CAM</term><def><p>Confusion assessment method</p></def></def-item><def-item><term>CDR</term><def><p>Clinical dementia rating scale</p></def></def-item><def-item><term>CFS</term><def><p>Chronic fatigue syndrome</p></def></def-item><def-item><term>CIRS</term><def><p>Cumulative illness rating scale</p></def></def-item><def-item><term>Cmax</term><def><p>Maximum plasma concentration</p></def></def-item><def-item><term>CNS</term><def><p>Central Nervous System</p></def></def-item><def-item><term>DSM-5</term><def><p>Diagnostic and statistical manual of mental disorders, fifth edition</p></def></def-item><def-item><term>ECG</term><def><p>Electrocardiogram</p></def></def-item><def-item><term>GFR</term><def><p>Glomerular filtration rate</p></def></def-item><def-item><term>HR</term><def><p>Heart rate</p></def></def-item><def-item><term>ICH</term><def><p>International conference on harmonization</p></def></def-item><def-item><term>ICU</term><def><p>Intensive care unit</p></def></def-item><def-item><term>IMP</term><def><p>Investigational medicinal product</p></def></def-item><def-item><term>IQCODE</term><def><p>Informant questionnaire on cognitive decline in the elderly</p></def></def-item><def-item><term>MAP</term><def><p>Mean Arterial Pressure</p></def></def-item><def-item><term>MDAS</term><def><p>Memorial delirium assessment scale</p></def></def-item><def-item><term>MDRD</term><def><p>Modification of diet in renal disease</p></def></def-item><def-item><term>MMSE-NR</term><def><p>Mini mental state evaluation &#x02013; Norwegian version</p></def></def-item><def-item><term>NYHA</term><def><p>New York Heart Association (functional classification of heart disease)</p></def></def-item><def-item><term>OSLA</term><def><p>Observational scale of level of arousal</p></def></def-item><def-item><term>RASS</term><def><p>Richmond agitation sedation scale</p></def></def-item><def-item><term>RCT</term><def><p>Randomised controlled trial</p></def></def-item><def-item><term>SQID</term><def><p>Single question in delirium</p></def></def-item></def-list></glossary><fn-group><fn><p>Bj&#x000f8;rn Erik Neerland and Karen Roksund Hov contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>Alasdair MacLullich has patents pending on computerised objective tests for inattention in delirium. Otherwise the authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>All authors made substantive intellectual contributions to the manuscript, the planning of the study and the writing of the protocol. TBW initiated the study. The study was designed by TBW, VBW, KRH and BEN. BEN and KRH contributed equally and are both primary authors to this manuscript. KRH and BEN are the daily responsible of running the study and collecting the data. EQ and VBW have particular responsibility for analysis and interpreting of pharmacological data and have contributed to the design of the pharmacological part of intervention. AM participated in all aspects of the project planning, in particular regarding the delirium diagnosis. ES carried out the randomisation procedure and has participated extensively in planning of the statistical analyses. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The trial is investigator-initiated and investigator-led, and is conducted independently of the pharmaceutical industry. The trial is financially supported by South-Eastern Norway Regional Health Authority and the University of Oslo. We are thankful to the staff of the department of Geriatric Medicine at Oslo University Hospital for their compliance with the project directives and their caring for the patients.</p><p>A full trial protocol can be accessed by contacting the corresponding author.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname><given-names>SK</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Saczynski</surname><given-names>JS</given-names></name></person-group><article-title>Delirium in elderly people</article-title><source>Lancet</source><year>2014</year><volume>383</volume><issue>9920</issue><fpage>911</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60688-1</pub-id><pub-id pub-id-type="pmid">23992774</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Murthy</surname><given-names>L</given-names></name><name><surname>Westby</surname><given-names>M</given-names></name><name><surname>Akunne</surname><given-names>A</given-names></name><name><surname>O'Mahony</surname><given-names>R</given-names></name></person-group><article-title>Diagnosis, prevention, and management of delirium: summary of NICE guidance</article-title><source>BMJ</source><year>2010</year><volume>341</volume><fpage>c3704</fpage><pub-id pub-id-type="doi">10.1136/bmj.c3704</pub-id><pub-id pub-id-type="pmid">20667955</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witlox</surname><given-names>J</given-names></name><name><surname>Eurelings</surname><given-names>LS</given-names></name><name><surname>de Jonghe</surname><given-names>JF</given-names></name><name><surname>Kalisvaart</surname><given-names>KJ</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>van Gool</surname><given-names>WA</given-names></name></person-group><article-title>Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis</article-title><source>JAMA</source><year>2010</year><volume>304</volume><issue>4</issue><fpage>443</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1013</pub-id><pub-id pub-id-type="pmid">20664045</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogseth</surname><given-names>M</given-names></name><name><surname>Wyller</surname><given-names>TB</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Juliebo</surname><given-names>V</given-names></name></person-group><article-title>Delirium is an important predictor of incident dementia among elderly hip fracture patients</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>31</volume><issue>1</issue><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1159/000322591</pub-id><pub-id pub-id-type="pmid">21212674</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>DH</given-names></name><name><surname>Muniz</surname><given-names>TG</given-names></name><name><surname>Keage</surname><given-names>H</given-names></name><name><surname>Rahkonen</surname><given-names>T</given-names></name><name><surname>Oinas</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><etal/></person-group><article-title>Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study</article-title><source>Brain</source><year>2012</year><volume>135</volume><issue>Pt 9</issue><fpage>2809</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/brain/aws190</pub-id><pub-id pub-id-type="pmid">22879644</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>TG</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Marcantonio</surname><given-names>ER</given-names></name><name><surname>Yap</surname><given-names>L</given-names></name><name><surname>Rudolph</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Delirium accelerates cognitive decline in Alzheimer disease</article-title><source>Neurology</source><year>2009</year><volume>72</volume><issue>18</issue><fpage>1570</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181a4129a</pub-id><pub-id pub-id-type="pmid">19414723</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eeles</surname><given-names>EM</given-names></name><name><surname>White</surname><given-names>SV</given-names></name><name><surname>O'Mahony</surname><given-names>SM</given-names></name><name><surname>Bayer</surname><given-names>AJ</given-names></name><name><surname>Hubbard</surname><given-names>RE</given-names></name></person-group><article-title>The impact of frailty and delirium on mortality in older inpatients</article-title><source>Age Ageing</source><year>2012</year><volume>41</volume><issue>3</issue><fpage>412</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ageing/afs021</pub-id><pub-id pub-id-type="pmid">22391613</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>N</given-names></name><name><surname>House</surname><given-names>AO</given-names></name><name><surname>Holmes</surname><given-names>JD</given-names></name></person-group><article-title>Occurrence and outcome of delirium in medical in-patients: a systematic literature review</article-title><source>Age Ageing</source><year>2006</year><volume>35</volume><issue>4</issue><fpage>350</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/ageing/afl005</pub-id><pub-id pub-id-type="pmid">16648149</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Ryan DJ, O'Regan NA, Caoimh R&#x000ed;&#x000f4;, Clare J, O'Connor M, Leonard M, et al. Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open. 2013; 3(1).</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korevaar</surname><given-names>JC</given-names></name><name><surname>van Munster</surname><given-names>BC</given-names></name><name><surname>de Rooij</surname><given-names>SE</given-names></name></person-group><article-title>Risk factors for delirium in acutely admitted elderly patients: a prospective cohort study</article-title><source>BMCGeriatr</source><year>2005</year><volume>5</volume><fpage>6</fpage></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Cole MG, Ciampi A, Belzile E, Dubuc-Sarrasin M: Subsyndromal delirium in older people: a systematic review of frequency, risk factors, course and outcomes. Int J Geriatr Psychiatry. 2012.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gool</surname><given-names>WA</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name></person-group><article-title>Systemic infection and delirium: when cytokines and acetylcholine collide</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9716</issue><fpage>773</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61158-2</pub-id><pub-id pub-id-type="pmid">20189029</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maclullich</surname><given-names>AM</given-names></name><name><surname>Ferguson</surname><given-names>KJ</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>de Rooij</surname><given-names>SE</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name></person-group><article-title>Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses</article-title><source>JPsychosomRes</source><year>2008</year><volume>65</volume><issue>3</issue><fpage>229</fpage><lpage>38</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Campion</surname><given-names>S</given-names></name><name><surname>Lunnon</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>CL</given-names></name><name><surname>Woods</surname><given-names>JF</given-names></name><name><surname>Deacon</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease</article-title><source>BiolPsychiatry</source><year>2009</year><volume>65</volume><issue>4</issue><fpage>304</fpage><lpage>12</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerejeira</surname><given-names>J</given-names></name><name><surname>Batista</surname><given-names>P</given-names></name><name><surname>Nogueira</surname><given-names>V</given-names></name><name><surname>Vaz-Serra</surname><given-names>A</given-names></name><name><surname>Mukaetova-Ladinska</surname><given-names>EB</given-names></name></person-group><article-title>The stress response to surgery and postoperative delirium: evidence of hypothalamic-pituitary-adrenal axis hyperresponsiveness and decreased suppression of the GH/IGF-1 Axis</article-title><source>J Geriatr Psychiatry Neurol</source><year>2013</year><volume>26</volume><issue>3</issue><fpage>185</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1177/0891988713495449</pub-id><pub-id pub-id-type="pmid">23864592</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitbart</surname><given-names>W</given-names></name><name><surname>Marotta</surname><given-names>R</given-names></name><name><surname>Platt</surname><given-names>MM</given-names></name><name><surname>Weisman</surname><given-names>H</given-names></name><name><surname>Derevenco</surname><given-names>M</given-names></name><name><surname>Grau</surname><given-names>C</given-names></name><etal/></person-group><article-title>A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients</article-title><source>Am J Psychiatry</source><year>1996</year><volume>153</volume><issue>2</issue><fpage>231</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1176/ajp.153.2.231</pub-id><pub-id pub-id-type="pmid">8561204</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalisvaart</surname><given-names>KJ</given-names></name><name><surname>de Jonghe</surname><given-names>JF</given-names></name><name><surname>Bogaards</surname><given-names>MJ</given-names></name><name><surname>Vreeswijk</surname><given-names>R</given-names></name><name><surname>Egberts</surname><given-names>TC</given-names></name><name><surname>Burger</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study</article-title><source>J Am Geriatr Soc</source><year>2005</year><volume>53</volume><issue>10</issue><fpage>1658</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53503.x</pub-id><pub-id pub-id-type="pmid">16181163</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skrobik</surname><given-names>YK</given-names></name><name><surname>Bergeron</surname><given-names>N</given-names></name><name><surname>Dumont</surname><given-names>M</given-names></name><name><surname>Gottfried</surname><given-names>SB</given-names></name></person-group><article-title>Olanzapine vs haloperidol: treating delirium in a critical care setting</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>3</issue><fpage>444</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00134-003-2117-0</pub-id><pub-id pub-id-type="pmid">14685663</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name></person-group><article-title>A double-blind trial of risperidone and haloperidol for the treatment of delirium</article-title><source>Psychosomatics</source><year>2004</year><volume>45</volume><issue>4</issue><fpage>297</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S0033-3182(04)70170-X</pub-id><pub-id pub-id-type="pmid">15232043</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>TA</given-names></name><name><surname>Eeles</surname><given-names>E</given-names></name><name><surname>Karapareddy</surname><given-names>V</given-names></name><name><surname>Muthuvelu</surname><given-names>P</given-names></name><name><surname>Chapple</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>B</given-names></name><etal/></person-group><article-title>A randomized controlled trial of quetiapine versus placebo in the treatment of delirium</article-title><source>J Psychosom Res</source><year>2010</year><volume>69</volume><issue>5</issue><fpage>485</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2010.05.006</pub-id><pub-id pub-id-type="pmid">20955868</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>E</given-names></name><name><surname>Britton</surname><given-names>AM</given-names></name><name><surname>Luxenberg</surname><given-names>J</given-names></name><name><surname>Wyller</surname><given-names>T</given-names></name></person-group><article-title>Antipsychotics for delirium</article-title><source>Cochrane Batabase Syst Rev</source><year>2007</year><volume>2</volume><fpage>CD005594</fpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Mattoo</surname><given-names>SK</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name></person-group><article-title>Usefulness of atypical antipsychotics and choline esterase inhibitors in delirium: a review</article-title><source>Pharmacopsychiatry</source><year>2011</year><volume>44</volume><issue>2</issue><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1273759</pub-id><pub-id pub-id-type="pmid">21394715</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray-Thomas</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>ME</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Brunner</surname><given-names>E</given-names></name><name><surname>Shatapathy</surname><given-names>CC</given-names></name><name><surname>Motsko</surname><given-names>S</given-names></name><etal/></person-group><article-title>Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database</article-title><source>Cardio Vascular Psychiatry Neurol</source><year>2013</year><volume>2013</volume><fpage>247486</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>E</given-names></name><name><surname>Luxenberg</surname><given-names>J</given-names></name><name><surname>Areosa</surname><given-names>SA</given-names></name><name><surname>Wyller</surname><given-names>TB</given-names></name></person-group><article-title>Benzodiazepines for delirium</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>1</volume><fpage>CD006379</fpage><pub-id pub-id-type="pmid">19160280</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eijk</surname><given-names>MM</given-names></name><name><surname>Roes</surname><given-names>KC</given-names></name><name><surname>Honing</surname><given-names>ML</given-names></name><name><surname>Kuiper</surname><given-names>MA</given-names></name><name><surname>Karakus</surname><given-names>A</given-names></name><name><surname>van der Jagt</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9755</issue><fpage>1829</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61855-7</pub-id><pub-id pub-id-type="pmid">21056464</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overshott</surname><given-names>R</given-names></name><name><surname>Karim</surname><given-names>S</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name></person-group><article-title>Cholinesterase inhibitors for delirium</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><volume>1</volume><fpage>CD005317</fpage><pub-id pub-id-type="pmid">18254077</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overshott</surname><given-names>R</given-names></name><name><surname>Vernon</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name></person-group><article-title>Rivastigmine in the treatment of delirium in older people: a pilot study</article-title><source>Int Psychogeriatr</source><year>2010</year><volume>22</volume><issue>5</issue><fpage>812</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1017/S1041610209991359</pub-id><pub-id pub-id-type="pmid">20353624</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>ZP</given-names></name><name><surname>Ferguson</surname><given-names>CN</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name></person-group><article-title>alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role.</article-title><source>Anaesthesia</source><year>1999</year><volume>54</volume><issue>2</issue><fpage>146</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2044.1999.00659.x</pub-id><pub-id pub-id-type="pmid">10215710</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>H</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name></person-group><article-title>Alpha(2) receptors and agonists in pain management</article-title><source>Curr Opin Anaesthesiol</source><year>2001</year><volume>14</volume><issue>5</issue><fpage>513</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/00001503-200110000-00009</pub-id><pub-id pub-id-type="pmid">17019139</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyar</surname><given-names>AS</given-names></name><name><surname>Yagmurdur</surname><given-names>H</given-names></name><name><surname>Fidan</surname><given-names>Y</given-names></name><name><surname>Topkaya</surname><given-names>C</given-names></name><name><surname>Basar</surname><given-names>H</given-names></name></person-group><article-title>Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy</article-title><source>J Neurosurg Anesthesiol</source><year>2008</year><volume>20</volume><issue>3</issue><fpage>174</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/ANA.0b013e318177e5eb</pub-id><pub-id pub-id-type="pmid">18580347</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichot</surname><given-names>C</given-names></name><name><surname>Ghignone</surname><given-names>M</given-names></name><name><surname>Quintin</surname><given-names>L</given-names></name></person-group><article-title>Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting?</article-title><source>J Intensive Care Med</source><year>2012</year><volume>27</volume><issue>4</issue><fpage>219</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1177/0885066610396815</pub-id><pub-id pub-id-type="pmid">21525113</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandharipande</surname><given-names>PP</given-names></name><name><surname>Pun</surname><given-names>BT</given-names></name><name><surname>Herr</surname><given-names>DL</given-names></name><name><surname>Maze</surname><given-names>M</given-names></name><name><surname>Girard</surname><given-names>TD</given-names></name><name><surname>Miller</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial</article-title><source>JAMA</source><year>2007</year><volume>298</volume><issue>22</issue><fpage>2644</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1001/jama.298.22.2644</pub-id><pub-id pub-id-type="pmid">18073360</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riker</surname><given-names>RR</given-names></name><name><surname>Shehabi</surname><given-names>Y</given-names></name><name><surname>Bokesch</surname><given-names>PM</given-names></name><name><surname>Ceraso</surname><given-names>D</given-names></name><name><surname>Wisemandle</surname><given-names>W</given-names></name><name><surname>Koura</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial</article-title><source>JAMA</source><year>2009</year><volume>301</volume><issue>5</issue><fpage>489</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.56</pub-id><pub-id pub-id-type="pmid">19188334</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>JR</given-names></name><name><surname>Wysong</surname><given-names>A</given-names></name><name><surname>van der Starre</surname><given-names>PJ</given-names></name><name><surname>Block</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Reitz</surname><given-names>BA</given-names></name></person-group><article-title>Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery</article-title><source>Psychosomatics</source><year>2009</year><volume>50</volume><issue>3</issue><fpage>206</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1176/appi.psy.50.3.206</pub-id><pub-id pub-id-type="pmid">19567759</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shehabi</surname><given-names>Y</given-names></name><name><surname>Grant</surname><given-names>P</given-names></name><name><surname>Wolfenden</surname><given-names>H</given-names></name><name><surname>Hammond</surname><given-names>N</given-names></name><name><surname>Bass</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study)</article-title><source>Anesthesiology</source><year>2009</year><volume>111</volume><issue>5</issue><fpage>1075</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e3181b6a783</pub-id><pub-id pub-id-type="pmid">19786862</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Zimmermann</surname><given-names>AE</given-names></name></person-group><article-title>Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients</article-title><source>Ann Pharmacother</source><year>2013</year><volume>47</volume><issue>6</issue><fpage>869</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1345/aph.1AR708</pub-id><pub-id pub-id-type="pmid">23719785</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>FY</given-names></name><etal/></person-group><article-title>Strategies for prevention of postoperative delirium: a systematic review and meta-analysis of randomized trials</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><issue>2</issue><fpage>R47</fpage><pub-id pub-id-type="doi">10.1186/cc12566</pub-id><pub-id pub-id-type="pmid">23506796</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajwa</surname><given-names>S</given-names></name><name><surname>Kulshrestha</surname><given-names>A</given-names></name></person-group><article-title>Dexmedetomidine: an adjuvant making large inroads into clinical practice</article-title><source>Ann Med Health Sci Res</source><year>2013</year><volume>3</volume><issue>4</issue><fpage>475</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.4103/2141-9248.122044</pub-id><pub-id pub-id-type="pmid">24379995</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cividjian</surname><given-names>A</given-names></name><name><surname>Toader</surname><given-names>E</given-names></name><name><surname>Wesseling</surname><given-names>KH</given-names></name><name><surname>Karemaker</surname><given-names>JM</given-names></name><name><surname>McAllen</surname><given-names>R</given-names></name><name><surname>Quintin</surname><given-names>L</given-names></name></person-group><article-title>Effect of clonidine on cardiac baroreflex delay in humans and rats</article-title><source>Am J Physiol Regul Int Comp Physiol</source><year>2011</year><volume>300</volume><issue>4</issue><fpage>R949</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00438.2010</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Hahn</surname><given-names>TH</given-names></name></person-group><article-title>The effect of clonidine pretreatment on the perioperative proinflammatory cytokines, cortisol, and ACTH responses in patients undergoing total abdominal hysterectomy</article-title><source>Anesth Analg</source><year>2000</year><volume>90</volume><issue>6</issue><fpage>1441</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/00000539-200006000-00035</pub-id><pub-id pub-id-type="pmid">10825337</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaudszun</surname><given-names>G</given-names></name><name><surname>Lysakowski</surname><given-names>C</given-names></name><name><surname>Elia</surname><given-names>N</given-names></name><name><surname>Tramer</surname><given-names>MR</given-names></name></person-group><article-title>Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials</article-title><source>Anesthesiology</source><year>2012</year><volume>116</volume><issue>6</issue><fpage>1312</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31825681cb</pub-id><pub-id pub-id-type="pmid">22546966</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>PM</given-names></name><name><surname>Carabine</surname><given-names>UA</given-names></name><name><surname>McClune</surname><given-names>S</given-names></name><name><surname>Orr</surname><given-names>DA</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name></person-group><article-title>Preanaesthetic medication with clonidine</article-title><source>BrJ Anaesth</source><year>1990</year><volume>65</volume><issue>5</issue><fpage>628</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/bja/65.5.628</pub-id><pub-id pub-id-type="pmid">2248839</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurito</surname><given-names>CE</given-names></name><name><surname>Baughman</surname><given-names>VL</given-names></name><name><surname>Becker</surname><given-names>GL</given-names></name><name><surname>DeSilva</surname><given-names>TW</given-names></name><name><surname>Carranza</surname><given-names>CJ</given-names></name></person-group><article-title>The effectiveness of oral clonidine as a sedative/anxiolytic and as a drug to blunt the hemodynamic responses to laryngoscopy</article-title><source>J Clin Anesth</source><year>1991</year><volume>3</volume><issue>3</issue><fpage>186</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/0952-8180(91)90157-I</pub-id><pub-id pub-id-type="pmid">1878231</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubino</surname><given-names>AS</given-names></name><name><surname>Onorati</surname><given-names>F</given-names></name><name><surname>Caroleo</surname><given-names>S</given-names></name><name><surname>Galato</surname><given-names>E</given-names></name><name><surname>Nucera</surname><given-names>S</given-names></name><name><surname>Amantea</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of clonidine administration on delirium and related respiratory weaning after surgical correction of acute type-A aortic dissection: results of a pilot study</article-title><source>Interact CardiovascThorac Surg</source><year>2010</year><volume>10</volume><issue>1</issue><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1510/icvts.2009.217562</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anavekar</surname><given-names>SN</given-names></name><name><surname>Jarrott</surname><given-names>B</given-names></name><name><surname>Toscano</surname><given-names>M</given-names></name><name><surname>Louis</surname><given-names>WJ</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects</article-title><source>EurJ ClinPharmacol</source><year>1982</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>E</given-names></name><name><surname>Schlegel</surname><given-names>J</given-names></name><name><surname>Fabbrini</surname><given-names>G</given-names></name><etal/></person-group><article-title>CLonidine treatment of alzheimer's disease</article-title><source>Arch Neurol</source><year>1989</year><volume>46</volume><issue>4</issue><fpage>376</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archneur.1989.00520400030015</pub-id><pub-id pub-id-type="pmid">2650662</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>M</given-names></name><name><surname>Bierer</surname><given-names>LM</given-names></name><name><surname>Kaminsky</surname><given-names>R</given-names></name><name><surname>Ryan</surname><given-names>TM</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name></person-group><article-title>Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study</article-title><source>Alzheimer Dis Assoc Disord</source><year>1989</year><volume>3</volume><issue>4</issue><fpage>224</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00002093-198900000-00005</pub-id><pub-id pub-id-type="pmid">2688700</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riekkinen</surname><given-names>M</given-names></name><name><surname>Jakala</surname><given-names>P</given-names></name><name><surname>Kejonen</surname><given-names>K</given-names></name><name><surname>Riekkinen</surname><given-names>P</given-names><suffix>Jr</suffix></name></person-group><article-title>The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease</article-title><source>Neuroscience</source><year>1999</year><volume>92</volume><issue>3</issue><fpage>983</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(99)00037-8</pub-id><pub-id pub-id-type="pmid">10426538</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Duenas</surname><given-names>M</given-names></name></person-group><article-title>Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo</article-title><source>Neurologia (Barcelona Spain</source><year>2003</year><volume>18</volume><issue>1</issue><fpage>2</fpage><lpage>6</lpage></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almenrader</surname><given-names>N</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Passariello</surname><given-names>M</given-names></name><name><surname>Haiberger</surname><given-names>R</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name><name><surname>Lonnqvist</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Absorption pharmacokinetics of clonidine nasal drops in children</article-title><source>Paediatr Anaesth</source><year>2009</year><volume>19</volume><issue>3</issue><fpage>257</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9592.2008.02886.x</pub-id><pub-id pub-id-type="pmid">19143953</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>MJ</given-names></name><name><surname>Wallin</surname><given-names>JD</given-names></name><name><surname>Chu</surname><given-names>LC</given-names></name></person-group><article-title>Plasma clonidine concentration and pharmacologic effect</article-title><source>Clin Pharmacol Ther</source><year>1981</year><volume>30</volume><issue>6</issue><fpage>729</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/clpt.1981.230</pub-id><pub-id pub-id-type="pmid">7307423</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keranen</surname><given-names>A</given-names></name><name><surname>Nykanen</surname><given-names>S</given-names></name><name><surname>Taskinen</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics and side-effects of clonidine</article-title><source>Eur J Clin Pharmacol</source><year>1978</year><volume>13</volume><issue>2</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/BF00609752</pub-id><pub-id pub-id-type="pmid">658114</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>DS</given-names></name><name><surname>Wing</surname><given-names>AM</given-names></name><name><surname>Reid</surname><given-names>JL</given-names></name><name><surname>Neill</surname><given-names>DM</given-names></name><name><surname>Tippett</surname><given-names>P</given-names></name><name><surname>Dollery</surname><given-names>CT</given-names></name></person-group><article-title>Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine</article-title><source>Clin Pharmacol Ther</source><year>1977</year><volume>21</volume><issue>5</issue><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1002/cpt1977215593</pub-id><pub-id pub-id-type="pmid">870272</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frisk-Holmberg</surname><given-names>M</given-names></name><name><surname>Edlund</surname><given-names>PO</given-names></name><name><surname>Paalzow</surname><given-names>L</given-names></name></person-group><article-title>Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients</article-title><source>Br J Clin Pharmacol</source><year>1978</year><volume>6</volume><issue>3</issue><fpage>227</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1978.tb04589.x</pub-id><pub-id pub-id-type="pmid">687501</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulheim</surname><given-names>D</given-names></name><name><surname>Fagermoen</surname><given-names>E</given-names></name><name><surname>Winger</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>AM</given-names></name><name><surname>Godang</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><etal/></person-group><article-title>Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial</article-title><source>JAMA pediatrics</source><year>2014</year><volume>168</volume><issue>4</issue><fpage>351</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2013.4647</pub-id><pub-id pub-id-type="pmid">24493300</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagermoen</surname><given-names>E</given-names></name><name><surname>Sulheim</surname><given-names>D</given-names></name><name><surname>Winger</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>AM</given-names></name><name><surname>Vethe</surname><given-names>NT</given-names></name><name><surname>Saul</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial</article-title><source>BMC Res Notes</source><year>2012</year><volume>5</volume><fpage>418</fpage><pub-id pub-id-type="doi">10.1186/1756-0500-5-418</pub-id><pub-id pub-id-type="pmid">22871021</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anavekar</surname><given-names>SN</given-names></name><name><surname>Howes</surname><given-names>LG</given-names></name><name><surname>Jarrott</surname><given-names>B</given-names></name><name><surname>Syrjanen</surname><given-names>M</given-names></name><name><surname>Conway</surname><given-names>EL</given-names></name><name><surname>Louis</surname><given-names>WJ</given-names></name></person-group><article-title>Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy</article-title><source>J Clin Pharmacol</source><year>1989</year><volume>29</volume><issue>4</issue><fpage>321</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1989.tb03335.x</pub-id><pub-id pub-id-type="pmid">2723120</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitbart</surname><given-names>W</given-names></name><name><surname>Rosenfeld</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Cohen</surname><given-names>K</given-names></name><name><surname>Passik</surname><given-names>S</given-names></name></person-group><article-title>The memorial delirium assessment scale</article-title><source>J Pain Symptom Manag</source><year>1997</year><volume>13</volume><issue>3</issue><fpage>128</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S0885-3924(96)00316-8</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Association</surname><given-names>AP</given-names></name></person-group><source>Diagnostic and Statistical Manual of Mental Disorders: DSM-5</source><year>2013</year><edition>5</edition><publisher-loc>Washington DC</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sands</surname><given-names>MB</given-names></name><name><surname>Dantoc</surname><given-names>BP</given-names></name><name><surname>Hartshorn</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>CJ</given-names></name><name><surname>Lujic</surname><given-names>S</given-names></name></person-group><article-title>Single question in delirium (SQiD): testing its efficacy against psychiatrist interview, the confusion assessment method and the memorial delirium assessment scale</article-title><source>Palliat Med</source><year>2010</year><volume>24</volume><issue>6</issue><fpage>561</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1177/0269216310371556</pub-id><pub-id pub-id-type="pmid">20837733</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sessler</surname><given-names>CN</given-names></name><name><surname>Gosnell</surname><given-names>MS</given-names></name><name><surname>Grap</surname><given-names>MJ</given-names></name><name><surname>Brophy</surname><given-names>GM</given-names></name><name><surname>O'Neal</surname><given-names>PV</given-names></name><name><surname>Keane</surname><given-names>KA</given-names></name><etal/></person-group><article-title>The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>10</issue><fpage>1338</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1164/rccm.2107138</pub-id><pub-id pub-id-type="pmid">12421743</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tieges</surname><given-names>Z</given-names></name><name><surname>McGrath</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>RJ</given-names></name><name><surname>Maclullich</surname><given-names>AM</given-names></name></person-group><article-title>Abnormal level of arousal as a predictor of delirium and inattention: an exploratory study</article-title><source>Am J Geriatric Psychiatry Off J Am Assoc Ger Psychiatry</source><year>2013</year><volume>21</volume><issue>12</issue><fpage>1244</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2013.05.003</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Del App. <ext-link ext-link-type="uri" xlink:href="http://www.edinburghdelirium.ed.ac.uk/">http://www.edinburghdelirium.ed.ac.uk/</ext-link>.</mixed-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname><given-names>SK</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Alessi</surname><given-names>CA</given-names></name><name><surname>Balkin</surname><given-names>S</given-names></name><name><surname>Siegal</surname><given-names>AP</given-names></name><name><surname>Horwitz</surname><given-names>RI</given-names></name></person-group><article-title>Clarifying confusion: the confusion assessment method. A new method for detection of delirium</article-title><source>AnnIntern Med</source><year>1990</year><volume>113</volume><issue>12</issue><fpage>941</fpage><lpage>8</lpage></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>R</given-names></name><name><surname>Siddiqi</surname><given-names>N</given-names></name><name><surname>Young</surname><given-names>J</given-names></name></person-group><article-title>The ethics of consent in delirium studies</article-title><source>J Psychosom Res</source><year>2008</year><volume>65</volume><issue>3</issue><fpage>283</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2008.05.023</pub-id><pub-id pub-id-type="pmid">18707952</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>D</given-names></name><name><surname>Treloar</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>FC</given-names></name><name><surname>Macdonald</surname><given-names>AJ</given-names></name></person-group><article-title>Ethical research in delirium: arguments for including decisionally incapacitated subjects</article-title><source>Sci Eng Ethics</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>169</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s11948-009-9120-y</pub-id><pub-id pub-id-type="pmid">19247810</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyller</surname><given-names>TB</given-names></name><name><surname>Watne</surname><given-names>LO</given-names></name><name><surname>Torbergsen</surname><given-names>A</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Frihagen</surname><given-names>F</given-names></name><name><surname>Juliebo</surname><given-names>V</given-names></name><etal/></person-group><article-title>The effect of a pre- and post-operative orthogeriatric service on cognitive function in patients with hip fracture. The protocol of the Oslo Orthogeriatrics Trial</article-title><source>BMC Geriatr</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1471-2318-12-36</pub-id><pub-id pub-id-type="pmid">22817102</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>NC</given-names></name><name><surname>Pressler</surname><given-names>M</given-names></name><name><surname>Nopoulos</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Ho</surname><given-names>BC</given-names></name></person-group><article-title>Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs</article-title><source>Biol Psychiatry</source><year>2010</year><volume>67</volume><issue>3</issue><fpage>255</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2009.08.040</pub-id><pub-id pub-id-type="pmid">19897178</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>FI</given-names></name><name><surname>Barthel</surname><given-names>DW</given-names></name></person-group><article-title>Functional evaluation: the barthel index</article-title><source>Maryland State Med J</source><year>1965</year><volume>14</volume><fpage>61</fpage><lpage>5</lpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>NB</given-names></name><name><surname>Gladman</surname><given-names>JR</given-names></name></person-group><article-title>The extended activities of daily living scale: a further validation</article-title><source>Disabil Rehabil</source><year>1992</year><volume>14</volume><issue>1</issue><fpage>41</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.3109/09638289209166426</pub-id><pub-id pub-id-type="pmid">1586760</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorm</surname><given-names>AF</given-names></name></person-group><article-title>A short form of the informant questionnaire on cognitive decline in the elderly (IQCODE): development and cross-validation</article-title><source>Psychol Med</source><year>1994</year><volume>24</volume><issue>1</issue><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1017/S003329170002691X</pub-id><pub-id pub-id-type="pmid">8208879</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CP</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Danziger</surname><given-names>WL</given-names></name><name><surname>Coben</surname><given-names>LA</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name></person-group><article-title>A new clinical scale for the staging of dementia</article-title><source>Br J Psychiatry J Mental Sci</source><year>1982</year><volume>140</volume><fpage>566</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1192/bjp.140.6.566</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><issue>3</issue><fpage>189</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Haugen</surname><given-names>P</given-names></name><name><surname>Gilje</surname><given-names>K</given-names></name><name><surname>Laake</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of short mental tests in the detection of mental impairment in old age</article-title><source>Comp gerontol Section A Clin Lab Sci</source><year>1988</year><volume>2</volume><issue>2</issue><fpage>87</fpage><lpage>93</lpage></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>GS</given-names></name><name><surname>Abrams</surname><given-names>RC</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>Shamoian</surname><given-names>CA</given-names></name></person-group><article-title>Use of the Cornell scale in nondemented patients</article-title><source>J Am Geriatr Soc</source><year>1988</year><volume>36</volume><issue>3</issue><fpage>230</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1988.tb01806.x</pub-id><pub-id pub-id-type="pmid">3339232</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>GS</given-names></name><name><surname>Abrams</surname><given-names>RC</given-names></name><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>Shamoian</surname><given-names>CA</given-names></name></person-group><article-title>Cornell scale for depression in dementia</article-title><source>Biol Psychiatry</source><year>1988</year><volume>23</volume><issue>3</issue><fpage>271</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0006-3223(88)90038-8</pub-id><pub-id pub-id-type="pmid">3337862</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvi</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>MD</given-names></name><name><surname>Grilli</surname><given-names>A</given-names></name><name><surname>Giorgi</surname><given-names>R</given-names></name><name><surname>Towers</surname><given-names>AL</given-names></name><name><surname>Morichi</surname><given-names>V</given-names></name><etal/></person-group><article-title>A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients</article-title><source>J Am Geriatr Soc</source><year>2008</year><volume>56</volume><issue>10</issue><fpage>1926</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2008.01935.x</pub-id><pub-id pub-id-type="pmid">18811613</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Draper</surname><given-names>EA</given-names></name><name><surname>Wagner</surname><given-names>DP</given-names></name><name><surname>Zimmerman</surname><given-names>JE</given-names></name></person-group><article-title>APACHE II: a severity of disease classification system</article-title><source>Crit Care Med</source><year>1985</year><volume>13</volume><issue>10</issue><fpage>818</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/00003246-198510000-00009</pub-id><pub-id pub-id-type="pmid">3928249</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldt</surname><given-names>KS</given-names></name></person-group><article-title>The checklist of nonverbal pain indicators (CNPI)</article-title><source>Pain Manage Nurs Off J Am Soc Pain Manage Nurs</source><year>2000</year><volume>1</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1053/jpmn.2000.5831</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Munster</surname><given-names>BC</given-names></name><name><surname>Bisschop</surname><given-names>PH</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Korevaar</surname><given-names>JC</given-names></name><name><surname>Endert</surname><given-names>E</given-names></name><name><surname>Wiersinga</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Cortisol, interleukins and S100B in delirium in the elderly</article-title><source>Brain Cogn</source><year>2010</year><volume>74</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.bandc.2010.05.010</pub-id><pub-id pub-id-type="pmid">20580479</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>BA</given-names></name><name><surname>Farber</surname><given-names>MO</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><name><surname>Perkins</surname><given-names>A</given-names></name><name><surname>Prasad</surname><given-names>NK</given-names></name><name><surname>Hui</surname><given-names>SL</given-names></name><etal/></person-group><article-title>S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - an exploratory analysis</article-title><source>Int J Gene Med</source><year>2013</year><volume>6</volume><fpage>855</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S51004</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osse</surname><given-names>RJ</given-names></name><name><surname>Fekkes</surname><given-names>D</given-names></name><name><surname>Tulen</surname><given-names>JH</given-names></name><name><surname>Wierdsma</surname><given-names>AI</given-names></name><name><surname>Bogers</surname><given-names>AJ</given-names></name><name><surname>van der Mast</surname><given-names>RC</given-names></name><etal/></person-group><article-title>High preoperative plasma neopterin predicts delirium after cardiac surgery in older adults</article-title><source>J Am Geriatr Soc</source><year>2012</year><volume>60</volume><issue>4</issue><fpage>661</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2011.03885.x</pub-id><pub-id pub-id-type="pmid">22316274</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>D</given-names></name><name><surname>Meagher</surname><given-names>D</given-names></name></person-group><article-title>Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence</article-title><source>J Aging Res</source><year>2011</year><volume>2011</volume><fpage>951403</fpage><pub-id pub-id-type="doi">10.4061/2011/951403</pub-id><pub-id pub-id-type="pmid">21766035</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>TD</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Pandharipande</surname><given-names>PP</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Shintani</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Associations of markers of inflammation and coagulation with delirium during critical illness</article-title><source>Intensive Care Med</source><year>2012</year><volume>38</volume><issue>12</issue><fpage>1965</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s00134-012-2678-x</pub-id><pub-id pub-id-type="pmid">22903241</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>JW</given-names></name><name><surname>Al-Qadhee</surname><given-names>NS</given-names></name><name><surname>Skrobik</surname><given-names>Y</given-names></name></person-group><article-title>Pharmacologic prevention and treatment of delirium in critically ill and non-critically ill hospitalised patients: A review of data from prospective, randomised studies</article-title><source>Best Pract Res Clin Anaesthesiol</source><year>2012</year><volume>26</volume><issue>3</issue><fpage>289</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2012.07.005</pub-id><pub-id pub-id-type="pmid">23040282</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trzepacz</surname><given-names>PT</given-names></name><name><surname>Bourne</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Designing clinical trials for the treatment of delirium</article-title><source>J Psychosom Res</source><year>2008</year><volume>65</volume><issue>3</issue><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2008.06.001</pub-id><pub-id pub-id-type="pmid">18707954</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farewell</surname><given-names>D</given-names></name><name><surname>Tahir</surname><given-names>TA</given-names></name><name><surname>Bisson</surname><given-names>J</given-names></name></person-group><article-title>Statistical methods in randomised controlled trials for delirium</article-title><source>J Psychosom Res</source><year>2012</year><volume>73</volume><issue>3</issue><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2012.06.002</pub-id><pub-id pub-id-type="pmid">22850260</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>D</given-names></name></person-group><article-title>Statistical methods for analysing longitudinal data in delirium studies</article-title><source>Int Rev Psychiatry</source><year>2009</year><volume>21</volume><issue>1</issue><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1080/09540260802675346</pub-id><pub-id pub-id-type="pmid">19219714</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>TA</given-names></name><name><surname>Farewell</surname><given-names>D</given-names></name><name><surname>Bisson</surname><given-names>J</given-names></name></person-group><article-title>Randomised control trials for delirium: current evidence and statistical methods</article-title><source>J Psychosom Res</source><year>2012</year><volume>72</volume><issue>1</issue><fpage>84</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2011.11.002</pub-id><pub-id pub-id-type="pmid">22200528</pub-id></element-citation></ref></ref-list></back></article>